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Abstract
Background: Human papilloma virus (HPV) types 6 and 11 account for 90 percent of anogenital warts (AGW).
Assessment of a potential reduction of the incidence of AGW following introduction of HPV vaccines requires
population-based incidence rates. The aim of this study was to estimate incidence rates of AGW in Germany,
stratified by age, sex, and region. Additionally, the medical practitioner (gynaecologist, dermatologist, urologist etc.)
who made the initial diagnosis of AGW was assessed.
Methods: Retrospective cohort study in a population aged 10 to 79 years in a population-based healthcare
insurance database. The database included more than 14 million insurance members from all over Germany during
the years 2004-2006. A case of AGW was considered incident if a disease-free period of twelve months preceded
the diagnosis. To assess regional variation, analyses were performed by federal state.
Results: The estimated incidence rate was 169.5/100,000 person-years for the German population aged 10 to 79
years. Most cases occurred in the 15 to 40 years age group. The incidence rate was higher and showed a peak at
younger ages in females than in males. The highest incidence rates for both sexes were observed in the city-states
Berlin, Hamburg and Bremen. In females, initial diagnosis of AGW was most frequently made by a gynaecologist
(71.7%), whereas in males, AGW were most frequently diagnosed by a dermatologist (44.8%) or urologist (25.1%).
Conclusions: Incidence of AGW in Germany is comparable with findings for other countries. As expected, most
cases occurred in the younger age groups. The frequency of diagnoses of AGW differs between sexes and women
and men receive treatment by doctors of different specialties.
Background
Anogenital warts (AGW) are a clinical manifestation of
human papillomavirus (HPV) infection. More than 100
HPV types have been recognised so far, of which more
than 40 can infect the anogenital tract [1,2]. Genital
HPV is a very common sexually transmitted infection
[3]. Some as high risk considered HPV types are asso-
ciated with the vast majority of cervical and other ano-
genital cancers [4,5]. HPV type 6 and in a smaller
proportion type 11 account for 90 percent of AGW
[4-6]. A tetravalent vaccine against HPV 6, 11, 16 and
18 which protects against AGW and other manifesta-
tions of HPV infection has been approved by the Eur-
opean Medicines Agency (EMA) in 2006 [7].
While AGW can resolve spontaneously, remain
unchanged or worsen when left untreated, often treat-
ment is chosen by the patients incurring treatment costs
[8]. Incidence rates of AGW have been reported for sev-
eral countries, showing a wide range of estimates [9-18],
even in studies originating from the same country [9,10].
Differences in reported incidence rates can be due to sev-
eral factors, including the use of different data sources,
study methods, and epidemiology of HPV between or
within countries. Studies reported differences between
sexes [9-11,13-17], unless the study population was
restricted to one sex, e.g. women [12,18,19].
A recent study estimated the annual incidence of AGW
in Germany as 171 per 100,000 women aged 14 to 25 years
[12]. However, since the study was based on a relatively
small convenience sample of physicians, population-based
data on AGW are lacking for Germany. We therefore used
a health insurance claims database including records on
more than 14 million persons to estimate incidence rates
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Furthermore, we investigated the specialty of the medical
practitioner who diagnosed AGW.
Methods
Study Design and Data Source
T h es t u d yw a sc o n d u c t e di nar e t r o s p e c t i v ec o h o r t
design. Source of data was the German Pharmacoepide-
miological Research Database (GePaRD) which has been
described elsewhere [20]. The GePaRD is a database of
more than 14 million insurees of all ages (approximately
17% of the German population) and covers all geogra-
phical regions of Germany. The database consists of
records of four large statutory health insurance compa-
nies (SHI). The data is not publicly available but other
institutions could apply for the data of the respecitve
SHIs and years. Statutory health insurance is mandatory
in Germany for all persons below a certain income
threshold. Above this threshold persons are permitted
to choose private insurance companies instead. How-
ever, given the relatively high threshold and the fact,
that some persons with a high income still elect statu-
tory health insurance, about 90% of the German popula-
tion remain in statutory health insurance. When this
project started, the database contained data for the years
2004-2006 for the different insurance companies. Since
then, the database has been extended to include data
from more recent years.
The GePaRD contains demographic information,
information on hospital admissions, ambulatory physi-
cian visits and prescriptions. The hospital data contains
information on admission and discharge dates and on
diagnostic and therapeutic procedures carried out in
hospital with the respective date. Ambulatory physician
visit claims data include ambulatory treatments, proce-
dures, and diagnoses. Since ambulatory physician visits
are reimbursed quarterly, ambulatory diagnoses can only
be allocated to a quarter of the year. All diagnoses, inpa-
tient and ambulatory diagnoses, are coded according to
the German Modification of the International Classifica-
tion of Diseases, 10
th Revision (ICD-10-GM) [21]. Preli-
minary analyses regarding the age and sex distribution,
the number of hospital admissions, and drug use
demonstrated that the database is generally representa-
tive of information published in official statistics [20].
Since the proportion of the population included in the
database varies across German federal states, regional
weights are necessary to obtain an estimate representa-
tive for the whole of Germany. The utilisation of health
insurance data for scientific research is regulated by the
Code of Social Law in Germany (SGB X). Approval for
the use of the data used in this study was granted by all
SHIs that contributed data to the study and the Federal
Ministry of Health. A detailed data protection concept
was approved by the Federal Ministry of Health which
precludes the use of data outside of the Bremen Insti-
tute for Prevention Research and Social Medicine.
Informed consent was not required by law, since the
study was based on pseudonymous data.
Definitions
Case identification
Diagnoses of AGW were ascertained by using the ICD-
10-GM (version valid in 2006) code A63.0, a specific
code for anogenital (venereal) warts. In order to esti-
mate incidence rates, we only considered newly diag-
nosed cases for this analysis. Each insuree had to have
an AGW free period of 12 months preceding the diag-
nosis. Cases were only considered from 2005 onwards,
since the year 2004 served to exclude prevalent cases of
AGW. In case of several diagnoses of AGW in the same
patient in different quarters, these were counted as a
single episode of AGW when the time interval between
two diagnoses of AGW was less than 12 months. Since
ambulatory data are only available by quarter, the date
of the ambulatory diagnosis was set to be at the middle
of each quarter. Some insurees could have had more
than one episode, thus persons could be counted as
incident cases more than once.
Cohort entry and exit
Cohort entry was on 1st of January 2005 or on the first
date afterwards, when patients had been continuously
insured 12 months preceding cohort entry and not had
a diagnosis of anogenital warts during this time period.
Cohort members had to be between 10 and 79 years of
age at cohort entry and remained in the cohort until the
first of the following dates: reaching of age 80, the day
of the first diagnosis of AGW, end or interruption of
insurance, death or end of the study period (31.12.2006).
Regional analysis
To investigate regional differences, we estimated inci-
dence rates by federal state. A specific characteristic of
the German federal states is that three major cities (Ber-
lin, Hamburg and Bremen) are federal states themselves,
so called city-states. These three city-states present den-
sely populated areas and can serve as a proxy for urban
regions. For the purpose of description of regional dif-
ferences regarding predominantly rural and urban
r e g i o n so nt h eo n es i d ea n dw e s t - e a s tc o m p a r i s o no n
the other side, federal states were classified into three
groups: city-states, other former West-German federal
states, and other former East-German federal states.
Specialty of medical practitioners
For the descriptive analysis of the specialty of the medi-
cal practitioner who initially diagnosed AGW, only the
first episode for each patient was considered. The speci-
alty of the medical practitioner was only available for
doctors not practicing in group practices. In the coding
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from group practices and therefore built a common
category. The specialties of medical practitioners
included in the analysis were gynaecologists, dermatolo-
gists, urologists, general practitioners/group practices,
surgeons, and internists. As no exact date, but only the
quarter was known for ambulatory diagnoses, it was not
possible to establish which medical practitioner diag-
nosed anogenital warts first in cases where more than
one ambulatory diagnosis was made in the same quarter.
In these cases, the specialty of the medical practitioner
was classified as “not identifiable”.
Statistical analysis
Estimation of incidence rates
The crude incidence rate and incidence rates stratified
by age, sex and region were calculated for the time per-
iod 2005 to 2006. The number of incident cases of the
respective stratum was divided by the total person time
of the respective stratum, expressed per 100,000 person-
years (py). Confidence intervals for incidence rates were
obtained from the Poisson distribution [22]. For com-
parison purposes with incidence rates reported in the
literature, incidence rates for the age group 14 to 65
years were calculated.
Incidence estimates were validated by independent
programming by a second programmer and all other
analyses by independent code review. All statistical ana-
lyses were conducted using SAS statistical software ver-
sion 8.2.
Standardisation of incidence rates
The incidence was stratified by sex, five year age groups
and the 16 federal states. An estimate of incidence for
Germany was obtained using population weights taking
age (14 categories), sex (2 categories) and federal state
(16 categories) into account. For each of the resulting
448 strata, population weights were obtained for the
German population in 2006 based on data from the
German Federal Statistical Office [23]. In order to
account for differences in regional age structure, inci-
dence rates for federal states were directly standardised
for the German population aged 10 to 79 years in 2006.
Assessment of the specialty of the medical practitioner
For the assessment of the specialty of the medical prac-
titioner who initially diagnosed AGW, only the first
diagnosis of AGW during the time in the cohort was
considered for each insuree.
Geographical distribution of incidence rates
The graphical presentation of the incidence rates in a
geographical map was conducted with ESRI® ArcMap™,
version 9.3. The classification of incidence rates for this
geographical mapping was performed using natural
breaks, where classes are based on natural groupings
inherent in the data and not on equal intervals. This
grouping method is based on the ArcGIS implementa-
tion of the Fisher-Jenks algorithm and minimizes differ-
ences between data values within classes and maximises
differences between classes [24,25].
Results
Incidence rates
In total, there were 11,206,905 insurees in the age group
10-79 in our cohort, who contributed 20,686,223 py.
There were 35,422 incident diagnoses of AGW, account-
ing to an annual crude incidence of 171.2 per 100,000
py in the studied period.
The overall weighted estimate for the 10 to 79 year old
population of Germany was very similar (169.5 per
100,000 py) and was 1.29 times higher for women than for
men (191.10 versus 147.66 per 100,000 py respectively).
The incidence rates were very similar in 2005 and
2006 (Table 1). When the incidence was further strati-
fied by age, females had higher incidence rates of AGW
than males in the younger age groups, with very little
difference after the age of 30 years (Figure 1).
The peak incidence was higher in females (627 per
100,000 py; 95% CI 601 to 654) than in males (457 per
100,000 py; 95% CI 433 to 482), and occurred at an earlier
age in females (20-24 years) than in males (25-29 years).
When the same age and sex population structure was
applied across all federal states, the differences persisted
between city-states and other regions on the one side
and between former East and West Federal States on
the other side (Figure 2).
When Germany was stratified into city-states (Berlin,
Hamburg, Bremen), former East Germany and former
West Germany (Figure 3), another feature of the inci-
dence distribution became apparent: In the city-states, a
high incidence among men extended over a wider age
range, so that in the age group 30-39 years the inci-
dence was higher among men than among women.
After the age of 40 years sex differences in AGW inci-
dence disappeared also in the city-states.
Specialty of medical practitioner who made the first
diagnosis of AGW
Women were mostly diagnosed by gynaecologists whilst
men were most frequently diagnosed by dermatologists,
followed by urologists (Figure 4).
Discussion
Previous studies estimated the incidence of AGW for
Australia [13,19,26], Canada [14,16], United States
[15,27], UK [9,10], Italy [18], Spain [19], France [28],
and Germany [12]. While due to the use of different
data sources, study methods and reporting of the inci-
dence for various age ranges a direct comparison is diffi-
cult, some observations can be made. The overall
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Australia [26], with most other estimates around 150
per 100,000, matching well the estimates from the cur-
rent study. Another German study using a convenience
sample of gynaecologists found an incidence of 76 per
100,000 in Germany in women of all ages and 114 per
100,000 in women of the age group 14-65 [12]. Both
estimates were about 50% lower than estimates from the
current study using a systematic approach to obtain
population based data. Several studies reported also inci-
dence among females in the age group 20-24 years: with
861 per 100,000 the incidence was highest in Australia
[17], followed by UK (672 per 100,000) [9] - both
slightly higher than the estimates from the current study
(627 per 100,000 from Figure 1). Substantially lower
rates were reported from Canada, 466 per 100, 000 in
Table 1 Crude incidence rates of anogenital warts by age and sex
Year Age group
(years)
Sex Person-time* Cases Incidence
rates**
95% Confidence interval**
2005 10-79 Female 56.85 10,999 193.47 189.87 to 197.12
Male 45.74 6,613 144.57 141.10 to 148.09
Total 102.59 17,612 171.67 169.14 to 174.22
14-65 Female 46.43 10,676 229.93 225.59 to 234.33
Male 36.93 6,339 171.64 167.44 to 175.92
Total 83.36 17,015 204.11 201.05 to 207.20
2006 10-79 Female 57.59 10,901 189.30 185.76 to 192.89
Male 46.69 6,907 147.95 144.48 to 151.48
Total 104.27 17,808 170.78 168.29 to 173.31
14-65 Female 46.60 10,586 227.19 222.88 to 231.56
Male 37.34 6,645 177.97 173.72 to 182.31
Total 83.93 17,231 205.30 202.24 to 208.39
* in 100,000 person-years
** per 100,000 person-years
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Figure 1 Incidence rates of anogenital warts by 5 year age groups in males and females for Germany in 2005 to 2006.
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with the lower overall incidence of genital warts in
Canada.
The peak incidence at a younger age in women than
in men observed in our study is consistent with findings
from several previous studies [16,17,27]. The overall sex
differences in incidence rates of AGW reported in the
literature vary. While Castellsagué et al.[11] reported
h i g h e ri n c i d e n c er a t e si nm e nt h a ni nw o m e n( 1 3 6 . 5 8
per 100,000 in men and 99.95 per 100,000 in women)
for the 14 to 64 year old population of Spain, Marra
et al.[16] reported higher overall incidence rates in men
than in women (131 per 100,000 in men and 121 per
100,000 in women in 2006), but also higher age specific
incidence rates for women than for men in the age
group 15 to 25 years. A Canadian study by Kliewer
et al. reported age standardised incidence rates over
time and showed a reversion of the sex ratio after the
year 2000 from higher incidence rates in women to
higher incidence rates in men [14].
Our study clearly demonstrated different pathways to
diagnosis of AGW for male and female patients. This
question was not assessed in previous studies, possibly
because of the methodological restrictions: some studies
were conducted with data from primary care or specia-
lised clinics [9,10], included only one or selected special-
ties of medical practitioners for case ascertainment
[11,12,18] or were population-based but did just not
investigate the specialty of the medical practitioner who
diagnosed AGW first [14,16]. However, another reason
Incidence 
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Hamburg
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Bremen
Figure 2 Geographical variation in incidence rates of
anogenital warts in Germany 2005 to 2006. Note: Incidence
rates are standardised for the sex and age distribution of the
German population in 2006 and are computed per 100,000 person-
years. Bremen and Bremerhaven constitute the city-state Bremen.
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in Germany in 2005 to 2006 by sex. City-states: the Federal states
Berlin, Bremen and Hamburg. West Germany: Federal states
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Germany: Federal states belonging to former East Germany without
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a n dt h a tt h es e xd i f f e r e n c eobserved for the diagnosing
medical practitioner is mainly associated with the orga-
nisation of the German health care system which
enables a direct access to specialists located in private
practices without consulting the general practitioner
first. These different pathways can also partly explain
the higher incidence noted in younger women than in
men: in women, AGW can be chance findings during
regular visits to the gynaecologist, while men have to
seek treatment actively.
Clear differences in incidence of AGW were found
between the territorial states of former East and West
Germany, and the city-states. The higher incidence in city-
states was not surprising as these regions were used as
proxies of urban regions and sexually transmitted diseases
are often more common in urban settings. The difference
between former East and West Germany is possibly also
related to a higher level of urbanisation in former West
Germany, but might also be an expression of many differ-
ences persisting between both former parts of Germany.
The comparison of just two years did not demonstrate
a n yd i f f e r e n c ei nA G Wi n c i d e n c e-o t h e rs t u d i e sw h i c h
compared longer time periods typically demonstrated an
increase in the incidence over time [14-16]. A decrease
in the incidence of AGW can be expected in Germany
starting from 2007 as in October 2006, the quadrivalent
HPV vaccine Gardasil® which protects from HPV types
6 and 11 was licensed for European countries including
Germany [29] and is recommended since July 2007 for
girls of 12-17 years of age [30].
Strengths and Limitations
The main strength of this study is the population based
nature of the data source which has been shown to be
adequately representative for Germany with respect to
age and sex [19]. The large sample of routinely collected
data diminishes potential selection bias which may result
from identification of patients in private practices, hos-
pitals or from clinics specialised in diagnosis and treat-
ment of sexually transmitted diseases, particularly if the
identification of patients was based on a convenience
sample of private practices or hospitals [8,10,11]. The
size of the data source also allowed estimation of inci-
dence rates in very narrow age strata for men and for
women and with high precision. In contrast to GP-
based studies [9,12,16], our study included patients diag-
nosed by all specialties of medical practitioners.
There are also some limitations. Patients of higher
socioeconomic status could have been underrepresented
due to their option to join private health insurances,
which includes about 10% of the German population.
Miscoding and the use of unspecific codes by health
care professions such as “viral warts” might have
happened and would have led to an underestimation of
the incidence in our study. Due to the diagnosis based
nature of the case ascertainment, only patients who
went to see a medical practitioner and who were diag-
nosed with AGW could be included.
Conclusions
We conducted an observational database study to esti-
mate incidence rates of AGW in Germany in a popula-
tion-based framework. Incidence of AGW was found in
the range of findings for other countries and was sub-
stantially higher than in a previous German study using
a convenience sample. High incidence rates were con-
centrated in the younger age groups, whereas consider-
able incidence rates were also noted above the age of 34
years in both, men and women. A reduction in the inci-
dence of AGW may be achievable through a vaccination
programme using a vaccine targeting the HPV types 6
and 11. Further research is recommended.
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